Piperidine

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

publication

Title:

Pharmacological studies on alicyclic amines, Report 1: Comparison of pharmacological activities of piperidine with those of other amines

Author:

Kasé Y, Miyata T, Yuizono T

Year:

1967

Bibliographic source:

Jpn. J. Pharmacol. 17, 475 - 490

Materials and methods

Principles of method if other than guideline:

Acute intraperitoneal toxicity

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

Piperidinium chloride

EC Number:

228-033-8

EC Name:

Piperidinium chloride

Cas Number:

6091-44-7

Molecular formula:

C5H11N.ClH

IUPAC Name:

piperidinium chloride

Details on test material:

TS-Freetext:
piperidine hydrochloride

Specific details on test material used for the study:

- Name of test material (as cited in study report): piperidine hydrochloride
- Analytical purity: no data

Test animals

Species:

mouse

Strain:

other: dd

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: no data
- Weight at study initiation: 18-22 g
- no further data

ENVIRONMENTAL CONDITIONS
- no further data

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

water

Doses:

50 - 500 mg/kg bw

No. of animals per sex per dose:

3

Control animals:

not specified

Details on study design:

- Duration of observation period following administration: 24 hours
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs

Statistics:

LD50 and its fiducial limit (p=0.05) were calculated by the method of Litchfield-Wilcoxon (J. Pharmac. exp. Ther. 96, 99, 1949) from the lethality observed within 24 hours.

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

330 mg/kg bw

Based on:

test mat.

95% CL:

269 - 450

Clinical signs:

At a dose of 50 mg/kg, the test substance did not elicit any change.
With 100 mg/kg, a decrease in spontaneous motilities and a slight depression of responses to external stimuli such as sound and touch were produced.
With 200 mg/kg, cease of spontaneous movement, disappearance of escape response from the stimulation, cyanosis, tachypnoea, piloerection and tremor of the whole body, and ataxia were observed.
With 250 mg/kg and 300 mg/kg, respiratory arrest occurred during convulsive seizures in 1 and 2 out of 6 cases, respectively.
General toxic symptoms of piperidine in mice were sedation (decrease of spontaneous motilities, and depression of escape reaction) with small doses, tremor and convulsion with large doses.